Investors Buy High Volume of Call Options on Chemours (NYSE:CC)

The Chemours Company (NYSE:CC) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 6,344 call options on the company. This is an increase of 65% compared to the typical daily volume of 3,835 call options.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $18.00 target price on shares of Chemours in a research note on Friday, January 16th. BMO Capital Markets restated an “outperform” rating and issued a $20.00 target price on shares of Chemours in a report on Monday, January 19th. Truist Financial raised their target price on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. UBS Group lowered their price target on shares of Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.67.

Chemours Stock Performance

Shares of CC stock opened at $20.42 on Friday. The stock’s 50-day moving average is $15.16 and its two-hundred day moving average is $14.41. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. Chemours has a 1 year low of $9.13 and a 1 year high of $21.85. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -9.20 and a beta of 1.63.

Chemours (NYSE:CC) last released its quarterly earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. Chemours had a positive return on equity of 35.27% and a negative net margin of 5.70%.The firm’s revenue was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 earnings per share. Analysts predict that Chemours will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Friday, February 27th will be given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, February 27th. Chemours’s dividend payout ratio (DPR) is presently -15.77%.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours reported quarterly EPS that beat expectations (company/analyst consensus). This helped limit the sell‑off by showing near‑term profitability on an adjusted basis. Chemours (CC) Beats Q4 Earnings Estimates
• Positive Sentiment: Board declared a quarterly dividend ($0.0875/share; ex‑dividend Feb. 27), which supports income investors and signals confidence in cash returns. The Chemours Company Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Unusual options activity showed elevated call buying, indicating some speculative or hedged bullish interest intraday. (Options volume spike noted in filings/newsflow.)
• Neutral Sentiment: Chemours issued FY‑2026 revenue guidance roughly in line with consensus (~$6.0–6.1B), but the company’s EPS guidance was unclear in the release — that ambiguity is leaving investors to re‑assess forward earnings potential. See company release/slide deck for details. Q4 Results — Slide Deck / Press Release
• Neutral Sentiment: Recent analyst coverage remains mixed with several buy/outperform opinions but a range of price targets; median target sits below recent highs, keeping upside expectations moderate. QuiverQuant coverage & analyst notes
• Negative Sentiment: Third‑party reporting highlighted a revenue miss vs. some estimates, a sharp drop in gross profit, a swing to operating and net losses on a GAAP basis, negative operating cash flow and elevated liabilities — all of which raise balance‑sheet and cash‑flow concerns. That analysis has been a major negative catalyst. Chemours Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Notable institutional selling in recent quarters (per holdings data) increases supply risk and may amplify downside if sentiment remains weak. Institutional holdings and flows

Institutional Trading of Chemours

Hedge funds have recently made changes to their positions in the company. Cooper Creek Partners Management LLC purchased a new stake in shares of Chemours during the 3rd quarter worth $63,103,000. Scopia Capital Management LP raised its stake in shares of Chemours by 71.7% during the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after buying an additional 1,401,539 shares during the last quarter. State Street Corp grew its stake in Chemours by 22.7% in the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after acquiring an additional 1,131,682 shares during the last quarter. Wolf Hill Capital Management LP acquired a new position in Chemours during the third quarter worth about $17,025,000. Finally, Sona Asset Management US LLC grew its position in shares of Chemours by 176.9% in the fourth quarter. Sona Asset Management US LLC now owns 1,651,275 shares of the specialty chemicals company’s stock valued at $19,469,000 after purchasing an additional 1,055,000 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.